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SUMMARY
Introduction: Major depression (MD), like other mood disorders, is considered a worldwide endemic pathology,
becoming one of the biggest public health problems. The hereditary factors of mood disorders have been studied for many
years and different chromosomal regions and genes have been involved in this physiopathological process.
Objective: To establish the association between allelic variants of the serotonin transporter gene (5-HTTLPR and VNTR)
and MD in a population with this diagnostic in the department of Caldas, Colombia.
Materials and methods: A case-control study was conducted with individuals older than 16 years of age born in the
department of Caldas. The sample was composed of 59 patients with the MD with family antecedents of the pathology and
59 controls paired by precedence, age, and gender. For the cases and controls selection the Diagnostic Interview for Genetic
Studies (DIGS) was used. Using the Hranilovic et al. protocol, the polymorphic regions in the promoter and third intron of
the Serotonin Transporter gene was amplified.
Results: It was not possible to find association between MD and the genetic or clinical variables. The absence of the short
allele of the promoter could act as a protective factor (OR=0.70 CI 95%=0.313 to 1.604), for the development of the pathology
in this population, and the presence of at least one copy of the 10 repetition alleles of the third intron could act as a risk factor
(OR: 1.25), but the wide confidence interval (CI 95%=0.38 to 2.64) does not permit supporting these conclusions.
Discussion: The results obtained in this population do not yield conclusive information related with the etiopathogeny
of MD, but do not contradict those obtained in other studies with bigger samples than ours. The broad confidence interval
does not support conclusions about the role as a risk factor for the 10 repetition alleles of the intron or the absence of the S
allele of the promoter as a protector factor. Further studies with larger population samples may help to clarify these facts.
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RESUMEN
Introducción: La depresión mayor (DM), como los demás trastornos del estado de ánimo, es considerada un síndrome
endémico en el contexto mundial. Por ello se ha constituido en uno de los más grandes problemas de salud pública. Los
factores hereditarios de los trastornos del estado de ánimo han sido estudiados por muchos años y en su proceso
fisiopatológico se han involucrado diferentes porciones cromosómicas y genes.
Objetivo: Establecer la asociación entre las variantes alélicas del gen del transportador de serotonina (5-HTTLPR y
VNTR) y la DM, en una población con este diagnóstico en el departamento de Caldas, Colombia.
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Materiales y métodos: Se realizó un estudio de casos y
controles en personas  mayores de 16 años originarias del
departamento de Caldas.  La muestra incluyó 59 pacientes
con el síndrome y antecedentes familiares de DM y 59 sujetos
controles pareados por procedencia, edad y género. Para la
selección de los casos y controles se utilizó el instrumento
Diagnostic Interview for Genetic Studies (DIGS). Se usó el
protocolo de Hranilovic et al., se amplificaron las porciones
polimórficas del promotor y el tercer intrón del gen del
transportador de serotonina.
Resultados: No se encontró asociación entre la DM y las
variables clínicas o genéticas. La ausencia del alelo corto del
promotor podría actuar como factor protector (OR=0.70 IC
95%= 0.313 a 1.604), para el desarrollo de este síndrome en
la población colombiana y la presencia de al menos una copia
del alelo de 10 repeticiones del tercer intrón, podría actuar
como factor de riesgo (OR: 1,25), pero el amplio intervalo de
confianza (IC 95%=0.38 a 2.64) no otorga soporte para estas
afirmaciones.
 Discusión: Los resultados obtenidos con la presente
población no entregan información concluyente relacionada
con la etiopatogenia de la DM, pero tampoco riñen con los
obtenidos en estudios similares con muestras de mayor
tamaño. La amplitud de los intervalos de confianza no
permiten emitir conclusiones definitivas acerca de factores
de riesgo (alelo 10 del intrón) o protectores (ausencia del
alelo S del promotor). Se requieren estudios con muestras
más grandes que otorguen mayor precisión y poder a estos
resultados.
Palabras clave: Depresión mayor; 5-HTTLPR; VNTR;
Colombia.
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Major depression (MD), like other mood disorders,
is considered a worldwide endemic pathology. There
are over 121-million people affected around the world,
becoming one of the biggest public health problems.
MD is by itself an important risk factor for the develop-
ment and death caused by cardiovascular disease. It has
been shown that as an independent variable, it increases
the mortality risk in the same manner as a cerebrovascular
accident or a case of congestive heart failure1.
Genetic predisposition is one of the points where
most attention has centered. The hereditary factors of
MD is recognized by family studies of twins and
adopted families2,3; but it is also clear that environmental
factors have a clear and critical impact on the develop-
ment of the pathology; in fact, only some individuals
with a family history of MD ever develop it4.
It is currently accepted that as with other psychiatric
illnesses, MD is a polygenic disorder5, although
mutations have been identified that dramatically increase
the possibility of developing the disorder in different
contexts6,7.
The serotonin transporter gene is one of the most
plausible candidates to being involved in the physio-
pathological process of mood disorders, but although
efforts are being made since the 1990s, results available
worldwide are not conclusive8-10.
At least three sources of variability in this gene have
been identified, of which the most studied are the
promoter polymorphous portion and that of the third
intron. Both portions come about because of a variable
number of tandem repetitions of an imperfect block.
For the promoter, the block repeated has 22 or 23 pairs
of bases and has been repeated between 16 and 22
times. The most frequently found variants are of 14
repetitions (short allele, S) and 16 repetitions (long
allele, L). The block repeated in the intron, has 17 pairs
of bases, found between 9 and 12 times. The most
frequently found alleles are those with 10 and 12
repetitions.
In the current work, we studied the possible
association among the promoter polymorphisms and
the Transporter third intron and the clinical behavior of
the major depressive condition in a population with this
diagnosis and a control group in the department of
Caldas, Colombia.
MATERIALS AND METHODS
We conducted a case and control study in individuals
over 16 years of age originating from the department of
Caldas in Colombia. The work was divided into two
methodological components (clinical and molecular);
for the clinical component, we reviewed the clinical
charts of personal consultation of psychiatrists and
from participating institutions, selecting individuals
over 16 years of age originating from the department of
Caldas with diagnosis of MD according to DSM IV and
CIE-10 criteria. The control for each case was selected
according to origin, age, and gender.
For the purpose of selecting the cases and controls,
the Diagnostic Interview for Genetic Studies (DIGS)
was used, with prior standardization to be administered
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by the research group. Upon evaluating the level of
agreement, two psychiatrists from the work group were
selected to evaluate the DIGS. One-hundred patients
with a history of major depressive disorder were
evaluated, of which 59 fulfilled the inclusion criteria.
All the individuals included in the current study signed
an informed consent form endorsed by the bioethical
committees in the institutions involved. Identities of
the subjects and their samples were only known by the
person who processed them, who assigned each subject
a code for their monitoring within the molecular
component of the study.
Genotyping. Using the protocol proposed by
Hranilovic et al.11, the polymorphous portions of the
promoter and the third intron of the serotonin transporter
gene were amplified. Total DNA was extracted from
each individual from 5 ml of peripheral blood, using a
commercially available kit (Promega).
To amplify via polymerase chain reaction (PCR) a
total volume of 20 µl was produced with both primers
at a concentration of 0.4 mM, 2.5 mM from each
nucleotide, 200 ng of DNA, 0.2 µl of the Go Taq
polymerase cocktail (Promega) and 4 µl enzyme buffer.
For amplification of the promoter, we began with
initial denaturation for a 2-minute period to go on to 35
cycles of 94°C, 61°C, and 72°C, for one minute in each
temperature, to end with a 7-minute final extension
cycle. The intron amplification program had 2-minutes
of initial denaturation, followed by 45 cycles of 94°C
(30 seconds), 53°C (30 seconds), and 72°C (45 seconds),
after which a final extension step was developed for a
5-minute period. For results tabulation, we designed an
Excel data base and the statistical analysis was carried
out in the SPSS version 14 statistical package via
univariate and bivariate analysis calculating the odds
ratio (OR) for association of variables of interest.
Molecular results were crossed with some clinical
variables extracted from the interview instrument.
RESULTS
Of the 100 patients with clinical history of MD, 59
fulfilled the inclusion criteria and each was assigned a
control maintaining parity between both groups (Table
1). The population analyzed was made up mostly of
women (81.4%), the mean age in the cases and controls
was 37 years of age. High school education was the
leading level of education and nearly 40% of the cases
reported having had suicide attempts. The general
characteristics of the population analyzed are shown in
Table 1.
Three promoter genotypes were identified, SS
(24.6%), SL (48.3%), and LL (27.1%). The three
genotypes found were distributed within the expected
range, per results obtained in similar populations (Table
2)12. Although similar values are presented, the genotype
frequencies of the case group reveal some differences
with the control group. At least one S allele (S/L=45.8%)
was presented in 76.3% of the cases, while 69.5% of the
controls had the same characteristic (S/L=50.8%).
Grouping all the individuals with at least one
promoter short allele did not generate different results
to those found previously (χ2: 0.203 and 0.352) (Table
3). Hence, the lack of a short allele could act as a
protective factor, but our broad confidence interval
does not permit emitting a definite conclusion
(OR=0.7086, CI 95%= 0.313 to 1.604).
Two alleles were identified in this population for the
third intron of the serotonin transporter, of the four
described worldwide. The 10/10 genotype had a
frequency of 16.9%; 10/12, 46.6%; and the 12/12 had
a 36.4% frequency (Table 4). These values keep to the
Table 1
General characteristics of study subjects
Variable                            Cases        Controls
Maximum age (years) 65 65
Minimum age 18 18
Mean age 37 37
Gender
    Men 11 11
    Women 48 48
Table 2
Genotypic frequencies of the promoter
Case/            Genotype of the promoter       Total
control          S/S            S/L         L/L
Case 18 (30.5) 27 (45.8)   14 (23.7) 59
Control 11 (18.7) 30 (50.8)   18 (30.5) 59
Total 29 (24.6) 57 (48.3)   32 (27.12)     118
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same tendencies expected for this population.
It was noted that 66.1% of the cases had at least one
intron 10 allele of (10/12=50.8%), against 59.7% of the
controls (10/12=42.4%). Upon evaluating the asso-
ciation between the clinical condition and the allelic
variants of the third intron, we found that the 10-
repetition allele could be considered a risk factor; but
the broad confidence interval does not permit emitting
a definite concept (OR=1.246 CI 95%=0.3832 to
2.6406).
No statistically significant dependence relation was
found between the third intron genotypes identified and
any of the clinical variables evaluated (suicide attempt,
age of illness onset, association with triggering factors).
Nine haplotypes were found and their frequencies
varied between 1.7% and 28.8%. The SL/1012 haplotype
was most commonly found at a frequency of 28.8%
among the case groups and 20.3% among the control
groups; while the SL/1010 haplotype was the most
infrequent among the case groups (3.4%) and the SS/
1010 haplotype was least found among control groups
(1.7%). No relationship was found between specific
haplotypes and the development of depressive symptoms
(χ2: 0.496) (Table 5).
DISCUSSION
The best reference for the current results is that
obtained from the study conducted by Ospina-Duque et
al.12, which studied a population in Antioquia, Colom-
bia. The frequency of the L/L genotype in our control
group (30.5%) is higher than that obtained in the study
mentioned (19.6%); while the case group presents
strong similarity between both studies. The S/S genotype
in this work was found less frequently within the
control group (18.7%) than that reported by the work
carried out in Antioquia (28.2%). But this tendency is
not kept in the case group (30.5% reported here and
26.2% reported in the work by Ospina-Duque et al.12).
Table 6 shows a detailed comparison of the results
obtained by Ospina-Duque et al.12 as well as those
obtained in our study.
Upon calculating the odds ratio, no association was
found between the promoter allelic variants and the
development of depressive conditions. It was not
possible to show a statistically significant association
among the promoter genotypes and the variables of
suicide attempt, age of illness onset, and possible
triggering factors like alcohol and illegal psychoactive
drugs.
The work presented in 2003 by Caspi et al.8 and
others confirming these results13,14 established the idea
that the impact of the short allele of this gene’s promoter,
lies at least partly, on the response to emotional stimuli
like child abuse and poor satisfaction of basic needs
during childhood. Seemingly, the presence of at least
Table 4
Genotypic frequencies of the intron
Case/control              Intron     Total
10/10 10/12 12/12
 Case 9 (15.3) 30 (50.8) 20 (33.9) 59
 Control 11 (17.3) 25 (42.4) 23 (39) 59
Table 5
Correlation of the SS/1010 haplotype
with the development of MD
                         Value Degrees            p
                                      of freedom
 χ2 7.386(a) 8 0.496
7.623 8 0.471
 N° of valid cases 118
Table 3
Clustered promoter case/control
Clustered promoter Value Degrees of freedom  Value of p       Two-tailed One-tailed
  χ2 1.620 1 0.203
  Fisher’s exact test 0.283 0.187
 N° of valid cases 118
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one of the short alleles from the promoter bears
functional impact, acting as an incomplete dominance
factor, for which it has been proposed that this is a
«sensitivity» factor that increases the deleterious
emotional impact of the stressful events15,16.
Worldwide findings show that 10- and 12-repetition
alleles of the intron, although in different proportions,
are the most frequent; situation presented in this study9.
The frequencies for each genotype present some
variability from one population to another. In the
Japanese population, the 10/10 genotype has a 0.5%
frequency, the 12/12 genotype has a frequency close to
80%, and the heterozygote is present in nearly 20% of
the population9. In Caucasian populations, a lower
frequency has been found for the 12/12 genotype
(~60%), in addition to a very superior frequency to that
found in other populations for the 9-repetition allele
(lacking in our work and in the Japanese population)17.
The European and American populations present greater
frequency in the 10/10 genotype than the rest (~15%),
while the other two genotypes have similar frequencies
amongst themselves (~45% for 10/12 and ~40% for 12/
12)9.
The results obtained through the analysis of the
present population do not furnish conclusive information
related to the etiopathogenesis of MD; but they do not
contradict those obtained in very similar studies with
greater-size samples. The current evidence reveals the
existence of at least a tangential relationship of the
serotonin transporter polymorphisms and the clinical
pattern of mood disorders. A physiopathological model
is accepted based on diminishing the transcriptional
rate the type-S promoter would have18, which has been
shown experimentally19. Diminishing the concentration
of serotonin in the cleft has been associated with
hyperactivity of the amygdale, an essential element for
the functional regulation of the limbic system.
These findings generate a series of new research
questions. The size of the confidence interval of our
work did not permit issuing definite conclusions about
the risk factors (10 repetition allele of the intron) or
factors like lack of promoter S allele, but it seems
plausible that they exist in our reference population.
For future studies, it would be interesting to bear in
mind some other clinical variables of the disorder,
particularly the response to antidepressants and the
long-term evolution with bigger-size samples that permit
greater precision and greater power of definition of the
results.
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